Keros Therapeutics, Inc.

NasdaqGM:KROS Rapport sur les actions

Capitalisation boursière : US$2.7b

Keros Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Keros Therapeutics possède un total de capitaux propres de $532.8M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $579.3M et de $46.4M.

Informations clés

0%

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$530.68m
Fonds propresUS$532.84m
Total du passifUS$46.44m
Total des actifsUS$579.27m

Mises à jour récentes de la santé financière

Recent updates

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13
Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19
We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27
Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Keros Therapeutics prices equity offering at $50

Nov 13

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de KROS ( $552.0M ) dépassent ses passifs à court terme ( $29.0M ).

Passif à long terme: Les actifs à court terme de KROS ( $552.0M ) dépassent ses passifs à long terme ( $17.4M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: KROS est sans dette.

Réduire la dette: KROS n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 120.2%.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: KROS dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: KROS dispose d'une marge de trésorerie suffisante pour 2.4 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 38.8 % chaque année.


Découvrir des entreprises saines